Similarly, as highlighted in [42], most tested clinical tumor samples and cancer-derived cell lines exhibited high DR5 expression and were sensitive to apoptosis induced by a bispecific anti-DR5 antibody, further supporting DR5 as a viable therapeutic target in oncology. Here, TNFRSF10B is linked to neoplasm.